India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The inspection is now closed, and no regulatory action has been recommended
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Subscribe To Our Newsletter & Stay Updated
